BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Toggle Summary BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit
NEW YORK and LOS ANGELES , Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern , MD, MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®
NEW YORK , Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent
View HTML
Toggle Summary BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
NEW YORK , Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update
NEW YORK , Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth
View HTML
Toggle Summary BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
NEW YORK , Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc ., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S.
View HTML
Toggle Summary BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference
NEW YORK , Feb. 17, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
Conference Call and Webcast @ 8:00 a.m. Eastern Time Today NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended
View HTML
Toggle Summary Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
NEW YORK and BOSTON , Feb. 27, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc . ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that Partners MS Center at Brigham and Women’s Hospital ,
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds